BACKGROUND: Substance P is a sensory nerve neuropeptide located near coronary vessels in the heart. Therefore, substance P may be one of the first mediators released in the heart in response to hypertension, and can contribute to adverse myocardial remodeling via interactions with the neurokinin-1 receptor. We asked: 1) whether substance P promoted cardiac hypertrophy, including the expression of fetal genes known to be re-expressed during pathological hypertrophy; and 2) the extent to which substance P regulated collagen production and fibrosis. METHODS AND RESULTS: Spontaneously hypertensive rats (SHR) were treated with the neurokinin-1 receptor antagonist L732138 (5mg/kg/d) from 8 to 24 weeks of age. Age-matched WKY served as controls. The gene encoding substance P, TAC1, was up-regulated as blood pressure increased in SHR. Fetal gene expression by cardiomyocytes was increased in SHR and was prevented by L732138. Cardiac fibrosis also occurred in the SHR and was prevented by L732138. Endothelin-1 was up-regulated in the SHR and this was prevented by L732138. In isolated cardiac fibroblasts, substance P transiently up-regulated several genes related to cell-cell adhesion, cell-matrix adhesion, and extracellular matrix regulation, however, no changes in fibroblast function were observed. CONCLUSIONS: Substance P activation of the neurokinin-1 receptor induced expression of fetal genes related to pathological hypertrophy in the hypertensive heart. Additionally, activation of the neurokinin-1 receptor was critical to the development of cardiac fibrosis. Since no functional changes were induced in isolated cardiac fibroblasts by substance P, we conclude that substance P mediates fibrosis via up-regulation of endothelin-1.
BACKGROUND:Substance P is a sensory nerve neuropeptide located near coronary vessels in the heart. Therefore, substance P may be one of the first mediators released in the heart in response to hypertension, and can contribute to adverse myocardial remodeling via interactions with the neurokinin-1 receptor. We asked: 1) whether substance P promoted cardiac hypertrophy, including the expression of fetal genes known to be re-expressed during pathological hypertrophy; and 2) the extent to which substance P regulated collagen production and fibrosis. METHODS AND RESULTS: Spontaneously hypertensiverats (SHR) were treated with the neurokinin-1 receptor antagonist L732138 (5mg/kg/d) from 8 to 24 weeks of age. Age-matched WKY served as controls. The gene encoding substance P, TAC1, was up-regulated as blood pressure increased in SHR. Fetal gene expression by cardiomyocytes was increased in SHR and was prevented by L732138. Cardiac fibrosis also occurred in the SHR and was prevented by L732138. Endothelin-1 was up-regulated in the SHR and this was prevented by L732138. In isolated cardiac fibroblasts, substance P transiently up-regulated several genes related to cell-cell adhesion, cell-matrix adhesion, and extracellular matrix regulation, however, no changes in fibroblast function were observed. CONCLUSIONS:Substance P activation of the neurokinin-1 receptor induced expression of fetal genes related to pathological hypertrophy in the hypertensive heart. Additionally, activation of the neurokinin-1 receptor was critical to the development of cardiac fibrosis. Since no functional changes were induced in isolated cardiac fibroblasts by substance P, we conclude that substance P mediates fibrosis via up-regulation of endothelin-1.
Authors: C J Dalsgaard; A Franco-Cereceda; A Saria; J M Lundberg; E Theodorsson-Norheim; T Hökfelt Journal: Cell Tissue Res Date: 1986 Impact factor: 5.249
Authors: William M Yarbrough; Rupak Mukherjee; Robert E Stroud; William T Rivers; J Marshall Oelsen; Jennifer A Dixon; Shaina R Eckhouse; John S Ikonomidis; Michael R Zile; Francis G Spinale Journal: J Thorac Cardiovasc Surg Date: 2011-11-04 Impact factor: 5.209
Authors: Gloria Fong; Ludvig J Backman; David A Hart; Patrik Danielson; Bob McCormack; Alex Scott Journal: J Orthop Res Date: 2012-07-26 Impact factor: 3.494
Authors: M F Barbe; B A Hilliard; P W Fisher; A R White; S P Delany; V J Iannarone; M Y Harris; M Amin; G E Cruz; S N Popoff Journal: Connect Tissue Res Date: 2019-08-23 Impact factor: 3.417
Authors: I Tong Mak; Jay H Kramer; Joanna J Chmielinska; Christopher F Spurney; William B Weglicki Journal: J Cardiovasc Pharmacol Date: 2015-01 Impact factor: 3.105
Authors: Giselle C Meléndez; Edward J Manteufel; Heather M Dehlin; Thomas C Register; Scott P Levick Journal: Heart Lung Circ Date: 2014-12-05 Impact factor: 2.975
Authors: Paul W Fisher; Yingjie Zhao; Mario C Rico; Vicky S Massicotte; Christine K Wade; Judith Litvin; Geoffrey M Bove; Steven N Popoff; Mary F Barbe Journal: J Cell Commun Signal Date: 2015-01-24 Impact factor: 5.782
Authors: Nagat Frara; Paul W Fisher; Yingjie Zhao; Joseph T Tarr; Mamta Amin; Steven N Popoff; Mary F Barbe Journal: Connect Tissue Res Date: 2017-04-12 Impact factor: 3.417
Authors: Scott P Levick; David R Soto-Pantoja; Jianli Bi; W Gregory Hundley; Alexander Widiapradja; Edward J Manteufel; Tancia W Bradshaw; Giselle C Meléndez Journal: Heart Lung Circ Date: 2018-09-02 Impact factor: 2.975